Drug-Drug Interactions
Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have bee...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (242 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546614404498 |
---|---|
ctrlnum |
(CKB)5400000000044842 (oapen)https://directory.doabooks.org/handle/20.500.12854/76871 (EXLCZ)995400000000044842 |
collection |
bib_alma |
record_format |
marc |
spelling |
Kim, Dong Hyun edt Drug-Drug Interactions Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (242 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions. English Research & information: general bicssc Biology, life sciences bicssc tadalafil ticagrelor drug-drug interaction pharmacokinetics plasma concentration CYP3A4 Loxoprofen CYP3A Dexamethasone Ketoconazole CYP2D6 O-desmethyltramadol physiologically-based pharmacokinetics tramadol (‒)-sophoranone CYP2C9 potent inhibition in vitro in vivo drug interaction low permeability high plasma protein binding biflavonoid cytochrome P450 drug interactions selamariscina A uridine 5′-diphosphoglucuronosyl transferase tissue-specific systemic exposure P-glycoprotein (P-gp) organic anion transporting polypeptide 1A2 (OATP1A2) Rumex acetosa fexofenadine chronic kidney disease drug–drug interactions polypharmacy adverse drug reactions Lexicomp subset analysis signal detection algorithms spontaneous reporting systems mechanism-based inhibition competitive inhibition non-competitive inhibition substrate inhibitor cytochromes P450 OATP1B1 OATP1B3 tyrosine kinase inhibitors drug-drug interactions migraine lasmiditan gepants monoclonal antibodies CYP1A1 CYP1A2 drug–drug interaction expression metabolism regulation drug transporter ubiquitination ixazomib DDI computational prediction in silico QSAR drug metabolism ADME CYP metabolic DDI P450 1A2 2B6 2C19 2C8 2C9 2D6 3A4 3-0365-2035-X 3-0365-2036-8 Lee, Sangkyu edt Kim, Dong Hyun oth Lee, Sangkyu oth |
language |
English |
format |
eBook |
author2 |
Lee, Sangkyu Kim, Dong Hyun Lee, Sangkyu |
author_facet |
Lee, Sangkyu Kim, Dong Hyun Lee, Sangkyu |
author2_variant |
d h k dh dhk s l sl |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Drug-Drug Interactions |
spellingShingle |
Drug-Drug Interactions |
title_full |
Drug-Drug Interactions |
title_fullStr |
Drug-Drug Interactions |
title_full_unstemmed |
Drug-Drug Interactions |
title_auth |
Drug-Drug Interactions |
title_new |
Drug-Drug Interactions |
title_sort |
drug-drug interactions |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (242 p.) |
isbn |
3-0365-2035-X 3-0365-2036-8 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT kimdonghyun drugdruginteractions AT leesangkyu drugdruginteractions |
status_str |
n |
ids_txt_mv |
(CKB)5400000000044842 (oapen)https://directory.doabooks.org/handle/20.500.12854/76871 (EXLCZ)995400000000044842 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Drug-Drug Interactions |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1787548858701578240 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04813nam-a2201285z--4500</leader><controlfield tag="001">993546614404498</controlfield><controlfield tag="005">20231214133700.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000044842</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/76871</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000044842</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kim, Dong Hyun</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug-Drug Interactions</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (242 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biology, life sciences</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tadalafil</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ticagrelor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug-drug interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacokinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasma concentration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP3A4</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Loxoprofen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP3A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Dexamethasone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ketoconazole</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2D6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">O-desmethyltramadol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">physiologically-based pharmacokinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tramadol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">(‒)-sophoranone</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP2C9</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">potent inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vitro</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in vivo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low permeability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high plasma protein binding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biflavonoid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytochrome P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">selamariscina A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">uridine 5′-diphosphoglucuronosyl transferase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tissue-specific</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">systemic exposure</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">P-glycoprotein (P-gp)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">organic anion transporting polypeptide 1A2 (OATP1A2)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Rumex acetosa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fexofenadine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chronic kidney disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug–drug interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">polypharmacy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adverse drug reactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Lexicomp</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">subset analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">signal detection algorithms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">spontaneous reporting systems</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mechanism-based inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">competitive inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-competitive inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">substrate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytochromes P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OATP1B1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">OATP1B3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug-drug interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">migraine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lasmiditan</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gepants</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">monoclonal antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1A1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP1A2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug–drug interaction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug transporter</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ubiquitination</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ixazomib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DDI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">computational prediction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">in silico</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">QSAR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug metabolism</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADME</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CYP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolic DDI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">P450</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">1A2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">2B6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">2C19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">2C8</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">2C9</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">2D6</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">3A4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2035-X</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2036-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Sangkyu</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kim, Dong Hyun</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Sangkyu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 06:02:31 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338246950004498&Force_direct=true</subfield><subfield code="Z">5338246950004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338246950004498</subfield></datafield></record></collection> |